In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

GLP-1s, which form the basis of Novo's Wegovy and rival Eli Lilly's Zepbound, work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors have now been eagerly ...

GLP-1s, which form the basis of Novo's Wegovy and rival Eli Lilly's Zepbound, work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors are now watching for ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...